Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedinotecMDNC 24 Debt-to-EBITDA is 0.01 as of May. 2026, which is 94% below its 10-year median of 0.16. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medinotec's Debt-to-EBITDA or its related term are showing as below:
MDNC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.78 Med: 0.16 Max: 16.38
Current: 0.01
During the past 5 years, the highest Debt-to-EBITDA Ratio of Medinotec was 16.38. The lowest was -16.78. And the median was 0.16.
MDNC's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.62
vs MDNC: 0.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medinotec Debt-to-EBITDA Related Terms
Medinotec Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medinotec's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDNC vs NVNO, APYX, RDGL: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Medinotec's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinotec Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medinotec's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (May. 2026) EBITDA data.
Medinotec (MDNC) has a Debt-to-EBITDA of 0.01 as of May. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medinotec. This is 94% below median its historical median of 0.16.
Is Medinotec's Debt-to-EBITDA too high?
Medinotec's current Debt-to-EBITDA of 0.01 is 94% below median its 10-year median of 0.16. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Medinotec's value of 0.01 is 99.4% below this industry median. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's Debt-to-EBITDA compare to NVNO and APYX?
Medinotec's Debt-to-EBITDA of 0.01 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-EBITDA is 1.62. Medinotec's value of 0.01 is 99.4% below this benchmark. While the company's 10-year median is 0.16 vs. the industry median of 1.62, Medinotec has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinotec's current Debt-to-EBITDA of 0.01 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medinotec. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current Debt-to-EBITDA is 0.01, which is 94% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current Debt-to-EBITDA of 0.01. The current Debt-to-EBITDA is 0.01, which is 94% below median its 10-year median of 0.16 and 99.4% below the Medical Devices & Instruments industry median of 1.62. Medinotec's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medinotec (MDNC), the current Debt-to-EBITDA is 0.01 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score
Get the complete analysis for MDNC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNC has been successfully added to your 
